Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD)
Phase 1
Not yet recruiting
- Conditions
- Graft Versus Host Disease
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- ViGenCell Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05276076
VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients
Phase 2
- Conditions
- Extranodal NK/T-cell Lymphoma
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- ViGenCell Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03671850
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷Keimyung University Daegu Dongsan Hospital, Daegu, Korea, Republic of
🇰🇷Hallym Univ. Medical Center, Gyeonggi-do, Korea, Republic of
News
No news found